Abivax SA

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: FR0012333284
EUR
89.20
-5.6 (-5.91%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

How big is Abivax SA?

22-Jun-2025

As of Jun 19, Abivax SA has a market capitalization of 340.65 million, classifying it as a Micro Cap company. There is no valid financial data available for net sales or net profit for the latest four quarters.

Market Cap: As of Jun 19, Abivax SA has a market capitalization of 340.65 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for net sales or net profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: As of December 2024, the shareholder's funds are reported at 40.58 million, and total assets amount to 205.23 million.

View full answer

What does Abivax SA do?

22-Jun-2025

Abivax SA is a clinical stage biopharmaceutical company focused on developing novel anti-viral compounds and therapeutic vaccines for severe infectious diseases, with a market cap of EUR 340.65 million. It currently has no earnings or dividends and significant negative return on equity.

Overview:<BR>Abivax SA is a clinical stage biopharmaceutical company in the Pharmaceuticals & Biotechnology industry, focusing on the discovery, development, and commercialization of novel anti-viral compounds and therapeutic vaccines against severe infectious diseases.<BR><BR>Financial Snapshot:<BR>Market cap: EUR 340.65 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making)<BR>Industry P/E: NA<BR>Dividend Yield: 0.00%<BR>Debt Equity: -1.22<BR>Return on Equity: -432.23%<BR>Price to Book: 8.39<BR><BR>Contact Details:<BR>Address: 5, rue de la Baume, Paris 8, PARIS None: 75008<BR>Tel: ['33 1 53830841']<BR>Fax: 33 4 94279261<BR>Website: http://www.abivax.com/

View full answer

Who are in the management team of Abivax SA?

22-Jun-2025

As of March 2022, the management team of Abivax SA includes Dr. Philippe Pouletty (Chairman), Ms. Joy Amundson, Dr. Claude Bertrand, Mr. Jean-Jacques Bertrand, Mr. Jerome Gallot, and Mr. Antoine Pau, who oversee the company's strategic direction and governance.

As of March 2022, the management team of Abivax SA includes the following individuals:<BR><BR>- Dr. Philippe Pouletty, Chairman of the Board<BR>- Ms. Joy Amundson, Director<BR>- Dr. Claude Bertrand, Director<BR>- Mr. Jean-Jacques Bertrand, Director<BR>- Mr. Jerome Gallot, Director<BR>- M. Antoine Pau, Director<BR><BR>This team is responsible for overseeing the strategic direction and governance of the company.

View full answer

Is Abivax SA technically bullish or bearish?

25-Jun-2025

As of October 1, 2023, Abivax SA exhibits a bearish technical stance overall, with mixed signals from indicators like the MACD and Bollinger Bands suggesting weak upward momentum.

As of 1 October 2023, the technical stance for Abivax SA is bearish with mild strength. The weekly MACD indicates a mildly bullish trend, but the monthly MACD is bearish, suggesting a lack of strong upward momentum. The Bollinger Bands are bearish on both weekly and monthly time frames, and daily moving averages also reflect a bearish sentiment. The Dow Theory shows a mildly bearish stance on both weekly and monthly charts. Although the KST is mildly bullish weekly, the overall indicators point to a bearish trend, particularly in the longer time frames.

View full answer
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Flat results in Dec 24

  • OPERATING CASH FLOW(Y) Lowest at EUR -253.6 MM
  • OPERATING PROFIT(Q) Lowest at EUR -98.1 MM
2

Risky -

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

EUR 7,711 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.22

stock-summary
Return on Equity

-34.31%

stock-summary
Price to Book

15.08

Revenue and Profits:
Net Sales:
(Quarterly Results - Dec 2025)
Net Profit:
-82 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-26.89%
0%
-26.89%
6 Months
26.88%
0%
26.88%
1 Year
1329.49%
0%
1329.49%
2 Years
571.69%
0%
571.69%
3 Years
1185.3%
0%
1185.3%
4 Years
264.83%
0%
264.83%
5 Years
392.82%
0%
392.82%

Abivax SA for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-211.39%
EBIT to Interest (avg)
-13.97
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.22
Sales to Capital Employed (avg)
0
Tax Ratio
3.64%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
33.94%
ROCE (avg)
0
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
15.92
EV to EBIT
-40.95
EV to EBITDA
-41.20
EV to Capital Employed
-228.82
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-34.31%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Abivax SA"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -90.75% vs -19.30% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-249.60",
          "val2": "-184.30",
          "chgp": "-35.43%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "28.50",
          "val2": "14.10",
          "chgp": "102.13%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-59.90",
          "val2": "-0.80",
          "chgp": "-7,387.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-336.10",
          "val2": "-176.20",
          "chgp": "-90.75%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Annual Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-249.60
-184.30
-35.43%
Interest
28.50
14.10
102.13%
Exceptional Items
-59.90
-0.80
-7,387.50%
Consolidate Net Profit
-336.10
-176.20
-90.75%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -90.75% vs -19.30% in Dec 2024

stock-summaryCompany CV
About Abivax SA stock-summary
stock-summary
Abivax SA
Pharmaceuticals & Biotechnology
ABIVAX is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of novel anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Company Coordinates stock-summary
Company Details
5, rue de la Baume, Paris 8 , PARIS None : 75008
stock-summary
Tel: 33 1 53830841
stock-summary
Registrar Details